VACCINEX INC

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

VCNX$1.41-61.4%Stored close · as of Dec 17, 2024

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Statements of Operations and Comprehensive Loss (Unaudited)

(in thousands, except share and per share data)

Three Months Ended June 30, · Six Months Ended June 30,
2024 · 2023 · 2024 · 2023
Revenue	$232	$	-	$336	$550
Costs and expenses:
Research and development	3,864		5,050	7,247	8,862
General and administrative	2,090		2,027	3,885	3,751
Total costs and expenses	5,954		7,077	11,132	12,613
Loss from operations	(5,722)		(7,077)	(10,796)	(12,063)
Interest expense	-		-	-	(1)
Financing costs - warrant liabilities	-		-	(28)	-
Change in fair value of warrant liabilities	156		-	1,362	-
Change in fair value of derivative asset	(81)		-	(81)	-
Other income (expense), net	16		17	15	42
Loss before provision for income taxes	(5,631)		(7,060)	(9,528)	(12,022)
Provision for income taxes	-		-	-	-
Net loss attributable to Vaccinex, Inc. common stockholders	$(5,631)		$(7,060)	$(9,528)	$(12,022)
Comprehensive loss	$(5,631)		$(7,060)	$(9,528)	$(12,022)
Net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	$(3.10)		$(24.54)	$(6.06)	$(45.78)
Weighted-average shares used in computing net loss per share attributable to Vaccinex, Inc. common stockholders, basic and diluted	1,817,520		287,719	1,572,388	262,623

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.